Attached files
file | filename |
---|---|
EX-99.2 - EXHIBIT 99.2 - Accelerate Diagnostics, Inc | v460898_ex99-2.htm |
EX-99.1 - EXHIBIT 99.1 - Accelerate Diagnostics, Inc | v460898_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported) | February 23, 2017 |
Accelerate Diagnostics, Inc. |
(Exact name of registrant as specified in its charter) |
Delaware |
(State or other jurisdiction of incorporation) |
001-31822 | 84-1072256 |
(Commission File Number) | (IRS Employer Identification No.) |
3950 South Country Club, Suite 470, Tucson, Arizona | 85714 |
(Address of principal executive offices) | (Zip Code) |
(520) 365-3100 |
(Registrant’s telephone number, including area code) |
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 | Results of Operations and Financial Condition. |
On February 27, 2017, Accelerate Diagnostics, Inc. (the “Company”) hosted a conference call to discuss its preliminary results of operations for the quarter and fiscal year ended December 31, 2016. A copy of the transcript of the conference call is attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 for Form 8-K, the information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 8.01. | Other Events. |
On February 23, 2017, the Company issued a press release announcing the U.S. Food and Drug Administration granted the Company’s de novo request to market the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for identification and antibiotic susceptibility testing of pathogens directly from positive blood culture samples. A copy of the Company’s press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference in its entirety.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits. The following materials are filed as exhibits to this Current Report on Form 8-K:
Exhibit | ||
Number | Description | |
99.1 |
Preliminary Earnings Call Transcript, February 27, 2017
| |
99.2 | Press Release, dated February 23, 2017 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ACCELERATE DIAGNOSTICS, INC. | |
(Registrant) | |
Date: March 1, 2017 | |
/s/ Steve Reichling | |
Steve Reichling | |
Chief Financial Officer |
EXHIBIT INDEX
Exhibit | ||
Number | Description | |
99.1 |
Preliminary Earnings Call Transcript, February 27, 2017
| |
99.2 | Press Release, dated February 23, 2017 |